[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"parasitic-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:parasitic-disease":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":4,"leadSponsor":44,"locationsCount":47},"100054447","activation-and-function-of-eosinophils-in-conditions-with-blood-or-tissue-eosinophilia-100054447",false,"NCT00001406","Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia","Eosinophil Activation and Function in Parasitic Infections and Other Conditions With Increased Tissue or Peripheral Blood Eosinophilia in Humans","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Stated willingness to comply with all study procedures and availability for the duration of the study\n2. Male or female, aged 1-100\n3. Ability of subject (or Legally Authorized Representative (LAR)) to understand and sign a written informed consent document\n\n   Eosinophilic Patients only:\n4. Documented peripheral blood count \\>1500\u002Fmm3, tissue eosinophilia (abnormal accumulation of eosinophils in the skin or other body tissues) or suspected eosinophilic end organ involvement\n5. Primary (non-NIH) physician for routine medical care\n\n   Relatives only:\n6. Extended family member of an eosinophilic participant on this protocol\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Any condition(s) or diagnosis, physical and\u002For psychological, that the investigator feels precludes the patient from participation in the study.\n\n   Relatives only:\n2. Females must not be pregnant","ALL","1 Year","100 Years",{"count":20,"type":21},800,"ESTIMATED","OBSERVATIONAL","This study will investigate how, why and under what conditions eosinophils (a type of white blood cell) become activated and will examine their function in immune reactions. Eosinophil counts often rise in response to allergies, asthma, and parasitic worm infections. They can also go up in uncommon autoimmune conditions and, rarely, in association with tumors. Elevated levels of these cells is called eosinophilia. Usually, eosinophilia causes no apparent symptoms, but in rare cases there may be local swelling and itching, allergic lung problems, heart disease or nerve damage caused by the release of toxic substances in these cells into body tissues.\n\nPatients 1 to 100 years of age with eosinophil counts greater than 750\u002Fml or an abnormal accumulation of eosinophils in the skin or body tissues may be eligible for this study. All participants will have a thorough medical history, physical examination and blood tests. Depending on the person's age and symptoms, other diagnostic tests may be done, including specialized studies of the eye, lungs, skin, bone marrow, nerves or heart. This is not a treatment study, and no experimental treatments will be offered. Patients who require treatment will receive standard medical care.\n\nCertain other procedures may be requested solely for research purposes. All participants will be asked to donate extra blood for laboratory studies investigating how immune cells and other immune substances in the blood act to stimulate a rise in eosinophils. In addition, some participants may undergo one or more of the following:\n\n* Annual Follow-up evaluations - Physical examinations and blood tests to evaluate changes in the patient's condition and eosinophil counts over time.\n* Bone marrow biopsy and aspiration will be recommended during the initial evaluation, and in certain patients at other times when it is important to look directly at the newly developing cells in the bone marrow. For this procedure an area of skin and bone is anesthetized with xylocaine (an anesthetic similar to that used by dentists), and a very sharp needle is used to sample the bone marrow for evaluation. Bone marrow biopsy and aspiration can have side effects of pain and\u002For bleeding into the skin and soft tissues at the site of the procedure. Rarely the area at the biopsy site can become infected, and is treated with antibiotics.\n* Genetic testing: Some of the blood drawn from you as part of this study will be used for genetic tests. Genetic tests can help researchers study how health or illness is passed on to you by your parents or from you to your children. Any genetic information collected or discovered about you or your family will be confidential.\n* Leukapheresis (only patients 18 years and older) to collect large numbers of certain cells - In this procedure, whole blood is collected through a needle placed in an arm vein. The blood circulates through a machine that separates it into its components. The white cells are then removed and the rest of the blood is returned to the body, either through the same needle used to draw the blood or through a second needle placed in the other arm....",[25,26,27,28,29],"Immune System Diseases","Eosinophilia","Helminthiasis","Hypersensitivity","Parasitic Disease",[31,32,33,34,35,36],"Eosinophils","Helminth Parasites","Hypereosinophilia","Allergy","Asthma","Natural History","RECRUITING","2026-06-03",{"date":40,"type":41},"2026-06-04","ACTUAL",{"date":43,"type":41},"1997-04-21",{"name":45,"class":46},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":68,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":88},"100601449","microbial-cell-free-metagenomic-sequencing-for-suspected-infections-in-adult-immunocompromised-outpatients-100601449","NCT07110636","Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients","A Prospective Randomized Basket Trial Evaluating the Clinical Utility of Plasma-based Microbial Cell-free Metagenomic Sequencing for Diagnosis and Management of Suspected Infections in Adult Immunocompromised Outpatients","OPTIMUM","Inclusion Criteria:\n\n* Basket Protocol\\* All participants must meet inclusion\n\n  1. Age ≥18\n  2. Included in one of the following immunocompromised groups: Solid organ transplant recipient (SOT) on chronic immunosuppression; Diagnosed with hematologic malignancy (HM) and\u002For recipient of a hematopoietic cell transplant (HCT); Diagnosed with a solid tumor and on specific types of active treatment; Recipient of drugs or novel biologics causing chronic immunosuppression; Diagnosed with an HIV infection; Diagnosed with inborn errors of immunity\n  3. Treating provider suspects infection and plans to obtain usual care diagnostic testing for the suspected infection (i.e., microbiologic testing)\n  4. Willing to provide research samples via blood draw\n  5. Willing and able to provide informed consent\n  6. Presenting for evaluation in the outpatient setting (includes telehealth)\n\n     \\*For Participants enrolled in Sub-Protocol A- Solid Organ Transplant\\*\n\n     All Sub-Protocol A subjects must meet the following:\n\n  \u003C!-- -->\n\n  1. Solid organ transplant recipient on transplant immunosuppression Non-lung recipients must meet one or more of the following characteristics: \\\u003C1 year from transplant; Augmented immunosuppression for suspected or confirmed rejection within the last 6 months; Confirmed systemic infection in last 6 months\n  2. Suspected infection defined by one or more of the syndromes: Cardiac; Lower Respiratory; Gastrointestinal \u002F Hepatobiliary; Genitourinary; Neurologic \u002F Ophthalmologic; Skin \u002F Soft tissue \u002F musculoskeletal; Not Otherwise Specified\n* For Participants enrolled in Sub-Protocol B- Hematological Malignancies and Transplant\\* All Sub-Protocol B subjects must meet the following:\n\n  1. Is included in at least one of the following groups: Hematologic malignancy (leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma) and at least one of the following: Received chemotherapy or other systemic anti-cancer therapy associated with immunosuppressive effects within 90 days (e.g., monoclonal antibodies associated with B-cell or plasma cell depletion, bi-specific t-cell engagers, BTK inhibitors, BCL-2 inhibitors, PI3K inhibitors) within the last 90 days Note: Checkpoint inhibitors are not included unless given in combination with an immunosuppressive agent; Relapsed disease with chemotherapy anticipated in 60 days; ANC \\\u003C500 within the last 72 hours; Hypogammaglobulinemia IgG \\\u003C400 within the last 30 days; Allogeneic stem cell transplant for any clinical indication and at least one of the following: Within 1-year post-transplant; On systemic immunosuppressive therapy for GVHD treatment or prophylaxis; Autologous stem cell transplant for hematologic malignancy and at least one of the following: Within 6 months post-transplant; ANC \\\u003C500 within the last 72 hours; B cell and plasma cell targeted CAR-T therapy for hematologic malignancy and at least one of the following: Within 6 months of CAR-T cell infusion; CD4 T-cell \\\u003C200 within the last 30 days; IgG \\\u003C 400 within the last 30 days; ANC \\\u003C500 within the last 72 hours; On systemic immunosuppressive therapy for CRS\u002FICANS\n  2. Suspected infection defined by one or more of the syndromes: Cardiac; Lower Respiratory; Gastrointestinal \u002F Hepatobiliary; Genitourinary; Neurologic \u002F Ophthalmologic; Skin \u002F Soft tissue \u002F musculoskeletal; Not Otherwise Specified\n\nExclusion Criteria:\n\n* Basket Protocol\\* All participants must not meet the following:\n\n  1. Active symptoms are likely attributed to non-infectious causes.\n  2. Any other clinically significant medical condition that, in the opinion of the treating provider, makes participation undesirable, including but not limited to severe psychiatric illness, etc.\n\n     \\*For Participants enrolled in Sub-Protocol A- Solid Organ Transplant\\*\n\n     All Sub-Protocol A subjects must not meet the following:\n\n  \u003C!-- -->\n\n  1. Patients who have been previously evaluated (including via telehealth) for the same clinical signs and symptoms at this institution and pathogen-directed usual care (UC), diagnostic testing was ordered during that prior encounter, with one or more diagnostic test results still pending.\n  2. Patients with a suspected or confirmed primary upper respiratory infection (e.g., viral pharyngitis, sinusitis, or uncomplicated bronchitis) unless there is clinical suspicion of a concurrent lower respiratory or systemic infection requiring further diagnostic evaluation.\n* For Participants enrolled in Sub-Protocol B- Hematological Malignancies and Transplant\\* All Sub-Protocol B subjects must not meet the following:\n\n  1. Patients that have been previously evaluated (including via telehealth) for the same clinical signs and symptoms at this institution and pathogen-directed usual care (UC) diagnostic testing was ordered during that prior encounter with one or more diagnostic tests results still pending.\n  2. Patients with a suspected or confirmed primary upper respiratory infection (e.g., viral pharyngitis, sinusitis, or uncomplicated bronchitis) unless there is clinical suspicion of a concurrent lower respiratory or systemic infection requiring further diagnostic evaluation.","18 Years",{"count":58,"type":21},2000,"INTERVENTIONAL",[61],"NA","This clinical trial is designed to evaluate if adding the Karius Spectrum™ plasma test to usual care diagnostic tests, compared to usual care testing alone, among immunocompromised participants presenting with suspected infection in the outpatient setting leads to faster infection diagnosis and treatment. Participants will give a blood sample one time to be used for the testing. Information about the participant's illness and any treatments within 30 days following enrollment will be recorded.",[64,65,66,67,29],"Infection","Infections, Bacterial","Infections, Fungal","Infection Viral",[69,70,71,72,73,74,75,76,77],"Karius","Karius Spectrum","Infection detection","metagenomic testing","Pathogen detection","Bacterial Infection","Fungal Infection","Parasitic Infection","Viral Infection","2026-01-28",{"date":80,"type":41},"2026-01-30",{"date":82,"type":41},"2025-10-27",{"date":84,"type":21},"2028-12-31",{"name":86,"class":87},"Karius, Inc.","INDUSTRY",6]